Table 1:
Clinical Characteristics of the Study Participants
| Characteristic | All Participants (n = 20) |
|---|---|
| Age (SD), y | 72.6 (11.1) |
| Female sex, n (%) | 4 (20) |
| %VP over seven follow-up days (SD) | 99.7 (0.2) |
| LVEF (SD), % | 31.7 (7.6) |
| Primary prevention ICD, n (%) | 16 (80) |
| NYHA class II, n (%) | 10 (50) |
| History of coronary heart disease, n (%) | 17 (85) |
| History of myocardial infarction, n (%) | 15 (75) |
| Location of infarction (% of patients with MI Hx), n (%) | |
| Anterior, n | 4 (27) |
| Inferoposterior, n | 9 (60) |
| Multiple (inferior and anterior, anterior and posterolateral) | 2 (13) |
| History of revascularization, n (%) | 13 (65) |
| Hypertension, n (%) | 10 (50) |
| Diabetes, n (%) | 7 (35) |
| Atrial fibrillation, n (%) | 9 (45) |
| History of nonsustained ventricular tachycardia, n (%) | 17 (85) |
| History of sustained ventricular tachycardia, n (%) | 4 (20) |
| Class III AA medications, n (%) | 6 (30) |
| β-blocker therapy, n (%) | 19 (95) |
| Digoxin therapy, n (%) | 4 (20) |
| Calcium channel blocker therapy, n (%) | 2 (10) |
| Diuretic therapy, n (%) | 9 (45%) |
| ACE inhibitor/angiotensin receptor blocker therapy, n (%) | 16 (80) |
AA: antiarrhythmic; ACE: angiotensin-converting enzyme; ICD: implantable cardioverter-defibrillator; LVEF: left ventricular ejection fraction; MI Hx: myocardial infarction history; NYHA: New York Heart Association; SD: standard deviation; VP: ventricular pacing.